Literature DB >> 26426162

Identification of immunodominant antigens for the laboratory diagnosis of toxocariasis.

Bin Zhan1, Ravi Ajmera2, Stefan Michael Geiger3, Marco Túlio Porto Gonçalves3, Zhuyun Liu1, Junfei Wei1, Patricia P Wilkins4, Ricardo Fujiwara3, Pedro Henrique Gazzinelli-Guimaraes3, Maria Elena Bottazzi1, Peter Hotez1.   

Abstract

OBJECTIVES: To identify immunodominant antigens of Toxocara canis recognised by Toxocara-infected sera as recombinant reagents for immunodiagnosis of toxocariasis.
METHODS: Pooled sera from human cases of toxocariasis were used to identify immunodominant antigens by immunoscreening a T. canis larval expression cDNA library. The positive clones were sequenced to reveal the identity of the antigens. The recombinant proteins were expressed in E. coli and then used to confirm their immunoreaction with sera of humans with toxocariasis. Two chosen antigens were also used to differentiate Toxocara infection from other helminth infections in mice.
RESULTS: Eleven antigens with immunodiagnostic potential were identified, including two C-type lectins (CTLs) that reacted strongly with the Toxocara-positive serum pool. The first CTL (Tc-CTL-1) is the same as TES-32, previously identified as a major immunodominant component of TES; the second CTL (Tc-CTL-2) is a novel C-type lectin sharing 83% amino acid sequence identity within the functional domain of Tc-CTL-1. The E. coli-expressed recombinant Tc-CTL-1 was strongly recognised by the Toxocara-positive serum pool or sera from animals experimentally infected with T. canis. Reactivity with recombinant Tc-CTL-1 was higher when the unreduced protein was used in an enzyme-linked immunosorbent assay (ELISA), dot-blot assay or Western blot test compared to the protein under reduced condition. Both recombinant Tc-CTL-1- and Tc-CTL-2-based ELISAs were able to differentiate T. canis infection from other helminth infections in experimentally infected mice.
CONCLUSIONS: Both Tc-CTL-1 and Tc-CTL-2 were able to differentiate Toxocara infection from other helminth infections and could potentially be used as sensitive and specific immunodiagnostic antigens.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  Tc-CTL-1; Tc-CTL-2; immunodiagnosis; recombinant protein; toxocariasis

Mesh:

Substances:

Year:  2015        PMID: 26426162     DOI: 10.1111/tmi.12607

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  6 in total

1.  A Lateral Flow Rapid Test for Human Toxocariasis Developed Using Three Toxocara canis Recombinant Antigens.

Authors:  Muhammad Hafiznur Yunus; Siti Naqiuyah Tan Farrizam; Izzati Zahidah Abdul Karim; Rahmah Noordin
Journal:  Am J Trop Med Hyg       Date:  2018-01-01       Impact factor: 2.345

2.  Seroprevalence of anti-Toxocara canis antibodies and associated risk factors among dog owners in the rural community of Nakhon Si Thammarat province, southern Thailand.

Authors:  Prasit Na-Ek; Udomsak Narkkul; Nonthapan Phasuk; Chuchard Punsawad
Journal:  Trop Med Health       Date:  2022-05-17

3.  Toxocara vitulorum cuticle glycoproteins in the diagnosis of calves' toxocariasis.

Authors:  Eman E El Shanawany; Soad E Hassan; Adel A-H Abdel-Rahman; Eman H Abdel-Rahman
Journal:  Vet World       Date:  2019-02-20

Review 4.  Human Toxocariasis: 2010 to 2020 Contributions from Brazilian Researchers.

Authors:  Pedro Paulo Chieffi; Susana Angelica Zevallos Lescano; Gabriela Rodrigues E Fonseca; Sergio Vieira Dos Santos
Journal:  Res Rep Trop Med       Date:  2021-05-19

5.  The 33.1 kDa Excretory/secretory Protein Produced by Toxocara canis Larvae Serves as a Potential Common Biomarker for Serodiagnosis of Toxocariasis in Paratenic Animals and Human.

Authors:  Huu-Hung Nguyen; Doan-Trung Vo; Thi-Tuyet-Trinh Thai; Thi-Thanh-Thao LE; Thanh-Dong LE; Nghia-Son Hoang
Journal:  Iran J Parasitol       Date:  2017 Jan-Mar       Impact factor: 1.012

6.  Urticaria and silent parasitism by Ascaridoidea: Component-resolved diagnosis reinforces the significance of this association.

Authors:  Marta Viñas; Idoia Postigo; Ester Suñén; Jorge Martínez
Journal:  PLoS Negl Trop Dis       Date:  2020-04-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.